Rituximab and ocrelizumab go head to head in randomized trial ...

Increasing the Ocrevus dose used in treating MS provided no additional benefit versus the approved regimen in trials with over 1,500 patients.

The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection for people with relapsing ...

Symptoms and frequency of relapses vary widely from person to person with the most common form of multiple sclerosis — and doctors aren’t entirely sure why. But, what exactly does a relapse look like?

MS is due to the body’s defence system, or immune system, attacking the insulating cover of myelin that protects the nerves. This damages the nerves and impairs their ability to pass on electric ...

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis (MS) have the relapsing-remitting (RR) disease course. This means that people have relapses -- also ...

Malaria and the Borrelia infection relapsing fever are diseases with similar symptoms that can occur simultaneously. In such cases, the malaria is moderated while the relapsing fever becomes more ...

Multiple sclerosis is a disorder of the immune system, where the myelin coating the nerve cells is damaged by antibodies formed by the defence system of the body. This affects the functioning of the ...